Publications by authors named "P Espinoza"

Background: The largest proportion of people at risk of catastrophic expenditures for surgical care live in low- and middle-income countries. This study aims to evaluate the financial impact among surgical patients at Kibuye Hope Hospital (KHH) in Burundi.

Methods: Data were collected from patients undergoing a surgical procedure at KHH from January to October 2019.

View Article and Find Full Text PDF

Pediatric cancer is a significant and growing burden in low- and middle-income countries. The objective of this project was to describe the factors influencing access to pediatric cancer care in Northern Tanzania using the Three Delays Model. This was a cross-sectional qualitative study conducted between June and August 2023 at Kilimanjaro Christian Medical Centre (KCMC).

View Article and Find Full Text PDF
Article Synopsis
  • Adeno-associated viruses (AAV) are effective for gene therapy, but face challenges like pre-existing immunity in patients and low efficiency in certain cell types.
  • This study uses a metabolic engineering method to enhance the production of extracellular vesicle-enclosed AAV (EV-AAV) by knocking out the PTDSS1 enzyme, resulting in a significantly higher yield and easier purification process.
  • The engineered EV-AAV9 showed improved cell entry and successful gene delivery in mouse brains, indicating that lipid metabolic engineering could enhance gene therapy vectors' effectiveness and development.
View Article and Find Full Text PDF

Microglia are critical innate immune cells of the brain. targeting of microglia using gene-delivery systems is crucial for studying brain physiology and developing gene therapies for neurodegenerative diseases and other brain disorders such as NeuroAIDS. Historically, microglia have been extremely resistant to transduction by viral vectors, including adeno-associated virus (AAV) vectors.

View Article and Find Full Text PDF

Adeno-associated viruses (AAV) are promising vectors for gene therapy due to their efficacy in vivo. However, there is room for improvement to address key limitations such as the pre-existing immunity to AAV in patients, high-dose toxicity, and relatively low efficiency for some cell types. This study introduces a metabolic engineering approach, using knockout of the enzyme phosphatidylserine synthase 1 (PTDSS1) to increase the abundance of extracellular vesicle-enclosed AAV (EV-AAV) relative to free AAV in the supernatant of producer cells, simplifying downstream purification processes.

View Article and Find Full Text PDF